TG Therapeutics(US:TGTX) ZACKS·2025-11-04 16:30Core Insights - TG Therapeutics (TGTX) reported earnings of $2.43 per share for Q3 2025, significantly exceeding the Zacks Consensus Estimate of 24 cents and up from 2 cents per share in the same quarter last year [1][7] - Revenues for Q3 totaled $161.7 million, representing a year-over-year increase of 92.8%, driven by strong demand for Briumvi, the company's sole marketed drug [2][7] - The company raised its 2025 revenue guidance to approximately $600 million, up from the previous estimate of $585 million, reflecting continued growth in Briumvi sales [11] Financial Performance - Total product revenues in Q3 were $159.3 million, an increase of 91.2% year over year, including $6.4 million from sales to licensing partner Neuraxpharm in ex-U.S. markets [4][8] - Briumvi's net product sales in the U.S. reached $152.9 million in Q3, up 84% year over year and 10% sequentially [8] - Research and development expenses surged 107.7% year over year to $35.5 million, attributed to higher manufacturing costs and ongoing clinical studies [9] - Selling, general, and administrative expenses rose 53.6% year over year to $51 million, driven by increased commercialization costs for Briumvi [10] Market Position - Shares of TG Therapeutics have increased 12% year to date, closely matching the industry's rise of 12.1% [3] - The company has ongoing studies for Briumvi targeting other autoimmune diseases and has commenced patient enrollment in a pivotal phase III program for a subcutaneous formulation [13] Future Outlook - For full-year 2025, net product sales of Briumvi are expected to be around $585 million in the U.S., an increase from the earlier projection of $570-$575 million [11] - Operating expenses for 2025 are anticipated to be around $300-$320 million [12]